1. Lang A, Siderowf A, Macklin EA, et al. Cinpanemab in early Parkinson's disease: phase 2 SPARK study results. International Parkinson and Movement Disorder Society Virtual Congress 2021: Sept 17–22, 2021: 408 (abstr).
2. Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models;Hebron;Hum Mol Genet,2013
3. Efficacy of nilotinib in patients with moderately advanced Parkinson disease: a randomized clinical trial;Simuni;JAMA Neurol,2021
4. A novel, selective c-Abl inhibitor, compound 5, prevents neurodegeneration in Parkinson's disease;Kwon;J Med Chem,2021
5. Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson's disease and dementia with Lewy bodies;Bargar;Acta Neuropathol Commun,2021